Checkpoint Therapeutics
在场
Checkpoint Therapeutics 的所有者是 Fortress Biotech.
Fortress Biotech 是一家在股票代码 FBIO (US) 下上市的公司。
Fortress Biotech 拥有 4家子公司，其中包括 Avenue Therapeutics、Checkpoint Therapeutics 和 Journey Medical Corp。
他们在：
高管
查看带有其 7 名主要高管的组织结构图
Checkpoint Therapeutics 搜索最多的简介
- James Oliviero, Presidentt, Chief Executive Officer and Director
- Christian Bechon, Director
- Barry Salzman, Director
创建提醒
跟踪 Checkpoint Therapeutics 的高管变动
生物技术
Fortress Biotech 拥有 2,337 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Aadi Bioscience 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
- OraSure Technologies has announced the acquisition of Sherlock Biosciences (公布2024十二月20号).
- SiteOne Therapeutics 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
生物技术 行业的其他推荐联系人
消息
Checkpoint Therapeutics 的最新新闻稿
- Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
- Press Releases
- Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
- Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
- Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
- Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
- GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
- Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
- View more press releases Close
